Novel multistranded, alternative, plasmid and helical transitional DNA and RNA microarrays: Implications for therapeutics

Pharmacogenomics

Volumn 10, Issue 5, 2009, Pages 895-914

  Gagna, Claude E ^a,b   Lambert, W Clark ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b NEW YORK INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

DNA and RNA structure; DNA microarrays; Multistranded and alternative nucleic acids; Pentaplex DNA; Pharmacogenomics; Quadruplex DNA; Triplex DNA

Indexed keywords

DOUBLE STRANDED DNA; NUCLEIC ACID; RNA; SINGLE STRANDED DNA;

ARTICLE; BIOMEDICINE; DNA STRAND; DNA STRUCTURE; DRUG RESEARCH; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE SEQUENCE; GENE TECHNOLOGY; GENETIC ANALYSIS; GENETIC ENGINEERING AND GENE TECHNOLOGY; GENOMICS; GENOTYPE; HUMAN; NUCLEIC ACID STRUCTURE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHARMACOGENOMICS; PROTEOMICS; RNA STRUCTURE; TRANSITIONAL STRUCTURAL CHEMOGENOMICS; TRANSITIONAL STRUCTURAL CHEMOPROTEOMICS; TRANSITIONAL STRUCTURAL NUCLEIC ACID MICROARRAY; TRANSITIONAL STRUCTURAL PHARMACOGENOMICS; TRANSITIONAL STRUCTURAL PHARMACOPROTEOMICS;

DNA; MICROARRAY ANALYSIS; MODELS, MOLECULAR; NUCLEIC ACID CONFORMATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PATENTS AS TOPIC; PHARMACOGENETICS; RNA; RNA, DOUBLE-STRANDED;

EID: 66849132737     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.27     Document Type: Article

References (63)

1. Wang G, Vasquez KM: Z-DNA, an active element in the gcnonic. Front. Biosci. 12, 4424-4438 (2007).
2. Lee C, Cho M: Vibrational dynamics of DNA: IV. Vibrational spectroscopic characteristics of A-, B, and Z-form DNA's. J. Chem. Phys. 126(14), 145102 (2007).
3. Lim W: Solitary excitations in B-Z DNA transition: a theoretical and numerical study. Phys. Rev. E. Stat. Nonlin. Soft Matter Phys. 75(3), E031918 (2007).
4. Placido D, Brown BA, Lowenhaupt K, Rich A, Athanasiadis A: A left-handed RNA double helix bound by the Zα domain of the RNA-editing enzyme ADAR1. Structure 15(4), 395-404 (2007).
5. Sinden RR: DNA Structure and Function. Academic Press, NY, USA (1994).
6. Zarling DA, Calhoun CJ, Hardin CC, Zarling AH: Cytoplasmic Z-RNA. Proc. Natl Acad. Sci. USA 84(17), 6117-6121 (1987).
7. Gagna CE, Lambert WC: The halting arrival of left-handed Z-DNA. Med. Hypotheses 60(3), 418-423 (2003).
8. Barton JK: Tris (phenanthroline) metal complexes: probes for DNA helicity. J. Biomol. Struct. Dyn. 1(3), 621-632 (1983).
9. Friedman AE, Kumar CV, Turro NJ, Barton JK: Luminescence of ruthenium(II) polypyridyls: evidence for intercalative binding to Z-DNA. Nucleic Acids Res. 19(10), 2595-2602 (1991).
10. Tsukamoto K, Odoko M, Ohishi H et al.: Stabilization of the left-handed Z-DNA with monoamines and polyamines. Nucleic Acids Symp. Ser. 49, 251-252 (2005).
11. Venter JC, Adams MD, Myers EW et al.: The sequence of the human genome. Science 291(5507), 1304-1351 (2001).
12. Sehgal A: Drug discovery and development using chemical genomics. Curr. Opin. Drug Discov. Devel. 5(4), 526-531 (2002).
13. Wadlow R, Ramaswamy S: DNA microarrays in clinical cancer research. Curr. Mol. Med. 5(1), 111-120 (2005).
14. Jeffery DA, Bogyo M: Chemical proteomics and its application to drug discovery. Curr. Opin. Biotechnol. 14(1), 87-95 (2003).
15. Beroza P, Villar HO, Wick MM, Martin GR: Chemoproteomics as a basis for post-genomic drug discovery. Drug Discov. Today 7(15), 807-814 (2002).
16. Shastry BS: Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J. 6(1), 16-21 (2006).
17. Zheng XF, Chan TF: Chemical genomics: a systematic approach in biological research and drug discovery. Curr. Issues Mol. Biol. 4(2), 33-43 (2002).
18. Zheng XFS, Chan TF: Chemical genomics in the global study of protein functions. Drug Discov. Today 7(3), 197-205 (2002).
19. Gaither LA: Chemogenomics approaches to novel target discovery. Expert Rev. Proteomics 4(3), 411-409 (2007).
20. Gagna CE, Winokur D, Lambert WC: The use of histotechnology, histochemical and immunohistochemical nucleic acid probes to qualify and quantify cell death in single-, double-, and multiple-stranded DNA in diseased and normal tissues. In: Recent Research Developments in Biophysics (Volume 3). Transworld Research Network, Kerala, India 207-233 (2004).
21. Gagna CE, Lambert WC: Chemistry and the genomic revolution. The Chemist 81(2), 21-26 (2004).
22. Gagna CE, Winokur D, Lambert WC: Cell biology, chemogenomics and chemoproteomics. Cell Biol. Int. 28(11), 755-764 (2004).
23. Gagna CE: Structural nucleic acid microarrays. Biochemistry 40(29), 8648 (2001).
24. Gagna CE, Chan N, Lambert WC: The effects of DNA and protein structure on cancer gene expression. Protein Sci. 13(Suppl. 1), 152 (2004) (Poster-312, 18th Symp. Prot. Soc.)
25. Gagna CE, Lambert WC: Effects of nucleic acid structure on normal gene expression. J. Histochem. Cytochem. 52(Suppl. 1), S50 (2004) (Poster-P11-P14, 12th Inter. Congr. Histochem. Cytochem.)
26. Gagna CE, Chan NJ, Lambert WC: Characterizing changes in the structure of normal and diseased genes which regulate gene expression: transitions in helical conformations of single-, double-, triple-, and four-stranded DNA. Mol. Biol. Cell 15, 445A (2004). (Poster-2466, 49th Ann. Mtg. Am. Soc. Cell Biol.)
27. Gagna CE, Law S, Jalaj S et al.: The effect of mustard gas on gene expression. FASEB J. 18(4), A572 (2004) (Poster 387.9, Exp. Biol. 2004).
28. Gagna CE, Chan N, Lambert WC: Structural transitional chemogenomics and structural transitional chemoproteomics: two novel drug discovery approaches. FASEB J. 19(4), A853 (2005) (Poster-521.4, Exp. Biol. 2005).
29. Gagna CE, Chan NJ, Spinelli D, Lambert WC: Regulation of gene expression by novel antisense technology, based on structures of DNA and RNA: structural transitional genomics (and proteomics). Biophys. J. 88 (1 Suppl. 2) 571A (2005) (Poster-2804, 49th Ann. Mtg. Biophys. Soc.)
30. Gagna CE, Lambert WC: Novel drug discovery and molecular biological methods via DNA, RNA and protein changes using structure-function transitions: transitional structural chemogenomics, transitional structural chemoproteomics and novel multi-stranded nucleic acid microarray. Med. Hypotheses 67(5), 1099-1114 (2006).
31. Chan NJ, Gagna CE, Yam T, Lambert WC: Transitional structural chemogenomics. Microsc. Microanal. 12(Suppl. 2), 414-415 (2006).
32. Gagna CE, Chan NJ, Lambert WC: Novel drug discovery techniques and DNA microarray: transitional structural chemogenomics and transitional structural chemoproteomics. In: Recent Research Developments in Biopbysics (Volume 5). Transworld Research Network, Kerala, India 133-146 (2006).
33. Gagna CE, Lambert WC: Cell biology, chemogenomics and chemoproteomics - application to drug discovery. Expert Opin. Drug Discov. 2(3), 381-401 (2007).
34. Kalow W: Pharmacogenomics and personalized medicine. Fund. Clin. Pharmacol. 16(5), 337-342 (2002).
35. Marsh S, McLeod HL: Pharmacogenomics: from bedside to clinical practice. Hum. Mol. Genet. 15(1), R89-R93 (2006).
36. Guo Y, Shafer S, Weller P, Usuka J, Peltz G: Pharmacogenomics and drug development. Pharmacogenomics 6(8), 857-864 (2005).
37. Ross JS, Schenkein DP, Kashala O et al.: Pharmacogenomics. Adv. Anat. Pathol. 11(4), 211-220 (2004).
38. Eichelbaum M, Ingelman-Sundberg M, Evans WE: Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119-137 (2006).
39. Witherspoon DJ, Wooding S, Rogers AR et al.: Genetic similarities within and between human populations. Genetics 176(1), 351-359 (2007).
40. Evans E, McLeod HL: Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538-549 (2003).
41. Daly AK: Individualized drug therapy. Curr. Opin. Discov. Devel. 10(1), 29-36 (2007).
42. Ansari M, Krajinovic M: Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy. Curr. Opin. Pediatr. 19(1), 15-22 (2007).
43. Mendrick DL: Current trends and strategic directions in the use of pharmacogenomics to identify translational binmarkers. Curr. Opin. Drug Discov. Devel. 10(1), 37-42 (2007).
44. Rusnak J, Kisabeth M, Herbert DP, McNeil DM: Pharmacogenomics: a clinician's primer on emerging technologies for improved patient care. Mayo Clin. Proc. 76(3), 299-309 (2001).
45. Weinshilboum R, Wang L: Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu. Rev. Genomics Hum. Genet. 7, 223-245 (2006).
46. Regnstrom K, Burgess DJ: Pharmacogenomics and its potential impact on drug formulation development. Crit. Rev. Ther. Drug Carrier Syst. 22(5), 465-492 (2005).
47. Nguyen A, Desta Z, Flockhart A: Enhancing race-based prescribing precision with pharmacogenomics. Clin. Pharmacol. Ther. 81(3), 323-325 (2007).
48. Relling MV, Hoffman JM: Should pharmacogenomic studies be required for new drug approval? Clin. Pharmacol. Ther. 81(3), 425-428 (2007).
49. Beitelshees AL, McLeod HL: Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety. Trends Pharmacol. Sci. 27(9), 498-502 (2006).
50. Hines RN, McCarver DG: Pharmacogenomics and the future of drug therapy. Pediatr. Clin. North Am. 53(4), 591-619 (2006).
51. Ross JS, Symmans WF, Pusztai L, Hortobagyi GN: Pharmacogenomics and clinical biomarkers in drug discovery and development. Am. J. Clin. Pathol. 124(Suppl.), S29-S41 (2005).
52. Mendrick DL: Current trends and strategic directions in the use of pharmacogenomics to identify translational biomarkers. Curr. Opin. Drug Discov. Devel. 10(1), 37-42 (2007).
53. Haugland RP: Handbook of Fluorescent Probes. Ninth Edition. Molecular Probes Inc., OR, USA (2004).
54. Qu X, Trent JO, Fokt I, Priebe W, Chaires JB: Allosteric, chiral-selective drug binding to DNA. Proc. Natl Acad. Sci. USA 97, 12032-12037 (2000).
55. Blaszak RT, Potaman V, Sinden RR, Bissler JJ: DNA structural transitions within the PKD1 gene. Nucleic Acids Res. 27(13), 2610-2617 (1999).
56. Huppert JL: Four-stranded DNA: cancer, gene regulation and drug development. Philos. Transact. A Math Phys. Eng. Sci. 365(1861), 2969-2984 (2007).
57. Kiyama R, Oishi M: Protection of DNA sequences by triplex bridge formation. Nucleic Acids Res. 23(3), 452-458 (1995).
58. Trommsdorff M, Kochl S, Lingenhel A et al.: A pentanucleodde repeat polymorphism in the 5′ control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma levels in Caucasians. J. Clin. Invest. 96(1), 150-157 (1995).
59. The International HapMap Consortium: The International HapMap Project. Nature 426(6968), 789-796 (2003).
60. Meloni R, Khalfallah O, Biguet NF: DNA microarrays and pharmacogenomics. Pharmacol. Res. 49(4), 303-308 (2004).
61. Chin KV, Kong ANT: Applications of DNA microarrays in pharmacogenomics and toxicogenomics. Pharm. Res. 19(12), 1773-1778 (2002).
62. Plomin R, Schalkwyk L: Microarrays. Dev. Sci. 10(1), 19-23 (2007).
63. Kuo WP, Liu F, Trimarchi J, Punzo C et al.: A sequence-oriented comparison of gene expression measurements across different hybridization-based technologies. Nat. Biotechnol. 24(7), 832-840 (2006).